Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing therapeutics using its INTASYL® siRNA gene silencing technology to eliminate cancer.
Phio Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 - 10, 2025, providing an update on its ongoing Phase 1b clinical trial for skin cancer.
The company's lead clinical program focuses on an INTASYL compound, PH-762, to treat cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma.
Presentation at Conference
Phio Pharmaceuticals will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 - 10, 2025.
Lead Product Candidate
PH-762, an INTASYL compound, targets the PD-1 gene implicated in skin cancer treatment.
Clinical Trial Progress
Advancing to the anticipated final cohort for the INSTASYL siRNA lead product candidate PH-762.
- Phio Pharmaceuticals aims to enhance immune cells' ability to kill cancer cells through its gene silencing technology.
- The company's focus on skin cancer treatment through non-surgical methods presents potential advancements in immuno-oncology therapeutics.
Phio Pharmaceuticals' participation in the conference and progress with the clinical trial demonstrate significant strides in developing innovative treatments for skin cancer.